Abbott and Google announced a multi-year partnership on August 11, 2026 that will feed real-time glucose readings from Abbott’s over-the-counter Lingo biosensor directly into Google’s Health app, where an AI system called Google Health Coach will translate the raw numbers into personalized daily advice on meals, sleep, exercise and stress. The companies are framing it as a first-of-its-kind collaboration aimed at more than 115 million American adults who have prediabetes, a condition that, according to figures the companies cited, roughly 8 in 10 affected people do not even know they have.
A quiet epidemic hiding in plain sight
Prediabetes describes blood sugar levels that are higher than normal but not yet high enough to be classified as type 2 diabetes, and more than 2 in 5 American adults meet the criteria, according to figures released alongside the partnership announcement. The condition is largely reversible through diet and lifestyle changes, but because it typically produces no symptoms, the overwhelming majority of people who have it never find out until it has already progressed toward diabetes, at which point complications become harder to prevent. Continuous glucose monitors, originally developed and approved for people with diabetes who need to track blood sugar to manage insulin dosing, have increasingly been marketed to the broader public as a way to make invisible metabolic patterns visible in real time.
What the partnership actually does
Under the deal, data from Abbott’s Lingo sensor, a wearable that continuously tracks glucose levels without requiring a prescription, will appear inside the Google Health app alongside a user’s other health information such as sleep and activity data. Google Health Coach, the company’s AI-powered coaching feature, will then generate specific, contextual recommendations, for example suggesting a short walk after a meal to blunt a glucose spike, adjusting recommended meal timing based on a person’s sleep patterns the previous night, or recommending stress-management techniques when the AI detects a glucose spike correlated with a stressful period rather than food. Olivier Ropars, divisional vice president of Abbott’s Lingo business, framed the goal in preventive terms: “The biggest challenge in healthcare isn’t treating disease, it’s helping people stay healthier longer.” Rishi Chandra, vice president and general manager of Google Health, said the ambition is turning “complex health information into personalized guidance.”
Beyond an app: a large research study
The companies also announced plans to run what they describe as one of the largest real-world metabolic health studies conducted to date, combining continuous glucose monitoring data with wearable device data, laboratory test results and survey responses to examine how factors like sleep quality, physical activity and stress interact with glucose regulation, including among people who do not have diabetes at all. Lingo integrations inside the Google Health app are expected to roll out later in 2026, with the full Google Health Coach feature available through a Google Health Premium subscription on select devices.
The case for wider access to metabolic data
Supporters of consumer continuous glucose monitoring argue that making blood sugar data visible and actionable, paired with AI that can interpret trends a layperson would otherwise miss, could catch metabolic dysfunction years before a standard annual blood test would flag it, giving people a genuine chance to reverse prediabetes through lifestyle change rather than eventually needing medication for full-blown diabetes. Because roughly 90 million American adults are estimated to be living with prediabetes without knowing it, proponents see even modest early awareness as a meaningful public health win.
Reasons for skepticism
Critics of the broader consumer CGM trend caution that glucose monitors were designed and clinically validated for people who already have diabetes, and that normal, healthy glucose fluctuations in people without the condition can be misread as alarming by users unfamiliar with what a typical glucose curve looks like, potentially fueling unnecessary anxiety or overly restrictive eating behavior. There is also relatively limited independent, peer-reviewed evidence so far demonstrating that AI-generated coaching based on glucose data actually produces sustained behavior change or improved long-term health outcomes in people without diabetes, as opposed to short-term engagement with a new gadget. Some clinicians have also raised concerns about handing large volumes of sensitive metabolic data to two of the largest technology and healthcare companies in the world, questioning how that data might be used, shared or monetized beyond the stated coaching purpose.
What it means going forward
The Abbott-Google partnership signals that continuous glucose monitoring is moving decisively beyond its original clinical use case for diabetes management and into the much larger market of general wellness and preventive health, a shift that mirrors how heart rate and sleep tracking moved from medical devices into everyday consumer wearables over the past decade. The large-scale real-world study the companies plan to run could eventually generate the kind of independent evidence currently missing from this space, clarifying whether AI-driven glucose coaching genuinely improves outcomes at population scale or mostly succeeds at selling more sensors and subscriptions. Either way, with the integration set to begin rolling out later this year, tens of millions of Americans will soon have the option to find out for themselves.
